title: Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users.
abstract: Hepatitis C virus (HCV) genotypes are distributed differently depending on geography and route of infection. We characterized the distribution of genotypes in a large cohort of patients with chronic hepatitis C in the South-east of France and evaluated the relative prevalence according to time of acquisition. One thousand, one hundred-and-eighty-three patients who were anti-HCV-positive were studied. HCV genotype distribution has changed significantly from the 1960s to 2000. The prevalence of genotype 1b decreased from 47% before 1978 to 18.8% in the 1990s while the prevalence of genotype 1a and 3a increased during the same period from 18% and 15.3% to 28.8% and 26.3%, respectively. The logistic regression model showed that genotype 1a was significantly more common in patients infected through intravenous drug injection odds ratio ((OR): 2.08, P < 0.01) and after 1990 (OR: 1.98, P < 0.05). Genotype 1b was significantly less frequent in patients infected through intravenous drug injection (OR: 0.17, P < 0.001) and has decreased since 1978 (OR: 0.27, P < 0.001). Genotype 3a was independently associated with intravenous drug injection (OR: 6.1, P < 0.001) and tattooing (OR: 8.01, P < 0.001) and was more frequent in the 1979-90 period (OR: 2.05 and 1.74, P < 0.001 and P < 0.05). Our results show a modification of HCV genotypes distribution over the last four decades due to an increase of intravenous drug use (IVDU) contamination and an evolution of HCV genotypes distribution only in IVDU population characterized by a decrease of genotype 1b, an increase of genotype 3a from 1970 to 1990 and a higher increase of genotype 1a which is currently the predominant genotype in our population.
authors.affiliation: Department of Gastroenterology and Liver Unit, Hôpital Saint Joseph, France. mbourliere@hopital-saint-joseph.fr
authors.forename: M
authors.initials: M
authors.lastname: Bourlière
authors.forename: J M
authors.initials: JM
authors.lastname: Barberin
authors.forename: M
authors.initials: M
authors.lastname: Rotily
authors.forename: V
authors.initials: V
authors.lastname: Guagliardo
authors.forename: I
authors.initials: I
authors.lastname: Portal
authors.forename: L
authors.initials: L
authors.lastname: Lecomte
authors.forename: S
authors.initials: S
authors.lastname: Benali
authors.forename: C
authors.initials: C
authors.lastname: Boustière
authors.forename: H
authors.initials: H
authors.lastname: Perrier
authors.forename: M
authors.initials: M
authors.lastname: Jullien
authors.forename: G
authors.initials: G
authors.lastname: Lambot
authors.forename: R
authors.initials: R
authors.lastname: Loyer
authors.forename: O
authors.initials: O
authors.lastname: LeBars
authors.forename: R
authors.initials: R
authors.lastname: Daniel
authors.forename: H
authors.initials: H
authors.lastname: Khiri
authors.forename: P
authors.initials: P
authors.lastname: Halfon
mesh_terms: D000328:Adult; D005602:France / Q000453:epidemiology; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications / Q000453:epidemiology / Q000503:physiopathology / Q000821:virology*; D006801:Humans; D015995:Prevalence; D015819:Substance Abuse, Intravenous / Q000150:complications / Q000821:virology*; D013997:Time Factors